STAMFORD, Conn., Oct. 22, 2019 /PRNewswire/ -- With a combined 22 seasons in the league, veteran All Pro Tight End Jason Witten and the reigning, consecutive Defensive Player of the Year Aaron Donald can confidently tell you that a proper training routine integrates post-workout muscle recovery. Both decorated

NORTHBOROUGH, Mass., Oct. 22, 2019 /PRNewswire/ -- AllCare Plus Pharmacy/AllCare Access Services, Northeast's largest patient support services company, will h

ZURICH, Oct. 22, 2019 /PRNewswire/ -- Neurimmune welcomes the news that Biogen plans regulatory filing for aducanumab in Alzheimer's disease based on a new analysis of a larger data set from Phase 3 studies. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich. In 2007 Neurimmune and

WASHINGTON, Oct. 22, 2019 /PRNewswire/ -- Medicomp Systems, the leading provider of physician-driven, point of care solutions that fix EHRs, announced today that the United States Patent

BRUSSELS, Oct. 22, 2019 /PRNewswire/ -- Ovizio Imaging Systems, a company providing an innovative microscopic imaging technology to the bioprocessing market, today announces the execution of supply agreements with Celgene Corporation for the automation of certain engineered T cell manufacturing processes.Celgene will be using Ovizio's innovative on-lin

REDWOOD CITY, Calif., Oct. 22, 2019 /PRNewswire/ -- Revolution Medicines, Inc., a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced that preclinical in vivo data on the company's novel inhibitors of oncogenic RAS(ON) mutan

SAN FRANCISCO, Oct. 22, 2019 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced that promising preclinical data from two of its gene therapy-focused subsidiaries – Adrenas Therapeutics and Aspa Therapeutics – will be presented at the European Society of Gene and Cell Therapy (ESGCT) Conference, occurring in Ba

TAMPA, Florida, Oct. 22, 2019 /PRNewswire/ -- GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager (TriKE™) platform, announced today that Drs. Jeffrey Miller, Martin Felices and P

HOUSTON, Oct. 22, 2019 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced the expansion of Annamycin production commitments in response to management's assessment of positive AML clinical trial acti

MENLO PARK, Calif., Oct. 22, 2019 /PRNewswire/ -- Sight Sciences, Inc., today announced a new, single center study of glaucoma surgery patients published in the July 2019 issue of Clinical Ophthalmology, which shows that ab-interno microcatheterization and 360˚ viscodilation of Schlemm's Canal using one of the OMNI® Surg